Renal cancer commonly known as kidney cancer originates in the lining of the proximal convoluted tubule of the kidney. The renal cancer is caused by Von Hippel-Lindau (VHL) syndrome, obesity, smoking, high blood pressure, long-term dialysis, occupational exposure (for example asbestos workers). The symptoms of renal cancer include a lump or mass in the abdomen or side, blood in the urine, weight loss, fever, and lethargy. Several drugs for the treatment of renal cancer are currently available in the market.
The global renal cancer drugs market is likely to show significant growth during the forecast period. This is attributed to the rising incidences of renal cancer, increasing geriatric population, and approval of novel molecules to develop drugs. However, high prices of branded drugs to treat cancer and rising preference for generic drugs are expected to restrain the market for renal cancer drugs market.
The renal cancer drugs market is segmented into three broad categories: by type, by brand, and by geography. Based on type, the market is divided into clear cell, papillary (Types 1 and 2), chromophobe, oncocytic, and collecting duct. The renal cancer drugs market, by brand is categorized into Sutent (Sunitinib), Nexavar (Sorafenib), Afinitor (Everolimus), Votrient (Pazopanib), Inlyta (Axitinib), Avastin (Bevacizumab), Torisel (Temsirolimus), Proleukin (Aldesleukin), and others.
Geographically, the global renal cancer drugs market is segmented into North America, Europe, Asia and Rest of the World (RoW: Latin America, Pacific Countries, and Middle East & Africa). North America accounted for the largest share of global renal cancer drugs, by region in 2014. However, Asia is expected to be the fastest growing market during the forecast period.
Some of the major players in the global renal cancer drugs market include Active Biotech AB (Sweden), Amgen (U.S.), Bayer AG (Germany), Cipla Limited (India), F. Hoffmann-La Roche AG (Switzerland), Genentech, Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Onyx Pharmaceuticals Inc. (U.S.), Pfizer, Inc. (U.S.).
Benchmarking the rapid strategy shifts of the Top 100 companies in the Renal Cancer Drugs MarketRequest For Special Pricing